Also known as: JAK2 , U751
Test Contains (LOINC): Interpretation (43399-5)
Preferred Container: EDTA (Lavender Top) Tube
Handling Instructions
Refrigerate specimen after collection.
Client Transport Temperature: Refrigerated
Specimen Stability: Ambient: 3 Days; Refrigerated: 1 Month
Unsuitable Specimen: Clotted specimens. Frozen samples. Heparinized specimens.
Frequency: Monday, Friday
Expected Turn Around: 3 – 5 Days
Responsible Dept: Reference Lab
Methodology: Real-Time Polymerase Chain Reaction (RT-PCR)
ADDITIONAL INFORMATION
BCR-ABL1 negative myeloproliferative neoplasms include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The JAK2 exon 14 mutation V617F is found in 95% of cases of PV, 55% of ET, 60% of PMF, and 40% of blast phase myeloproliferative neoplasms. Testing for the JAK2 V617F mutation may be useful in evaluating unexplained erythrocytosis, thrombocytosis, or bone marrow fibrosis. Evaluation of other signs and symptoms of myeloproliferative neoplasms such as unusual thrombotic events, aquagenic pruritis, or splenomegaly may also benefit from JAK2 V617F testing. The JAK2 V617F qualitative test utilizes real-time polymerase chain reaction (PCR) to detect the NM_004972.3(JAK2):c.1849G>T (p.Val617Phe) nucleotide change. The limit of detection is 1.0% mutant alleles. Other mutations in the JAK2 gene or other mutations associated with myeloproliferative neoplasms are not detected.
Ordering Recommendation
For qualitative detection of JAK2 V617F mutation in whole blood specimens from patients with suspected myeloproliferative neoplasms.
Compliance Statement
This test was developed and its performance characteristics determined by Sonic Reference Laboratory (SRL). It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes and should not be regarded as investigational or for research. SRL is qualified to perform high complexity testing under the Clinical Laboratory Improvement Amendments (CLIA).
Notes: Replacement test for U750
Billing Status: Prior Authorization Required
